Zacks Investment Research upgraded shares of Intec Pharma Ltd. (NASDAQ:NTEC) from a sell rating to a hold rating in a report published on Wednesday.
According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
NTEC has been the topic of several other research reports. Oppenheimer Holdings, Inc. raised their price objective on shares of Intec Pharma from $10.00 to $15.00 and gave the stock an outperform rating in a research note on Thursday, September 21st. CIBC restated an outperform rating and issued a $15.00 price objective (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Finally, Roth Capital set a $10.00 price objective on shares of Intec Pharma and gave the stock a buy rating in a research note on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $12.25.
Shares of Intec Pharma (NASDAQ:NTEC) opened at 8.40 on Wednesday. The company has a 50-day moving average of $8.61 and a 200 day moving average of $8.61. The firm’s market capitalization is $115.40 million. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80.
An institutional investor recently raised its position in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. increased its position in Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 522,200 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the quarter. Migdal Insurance & Financial Holdings Ltd. owned approximately 3.80% of Intec Pharma worth $2,977,000 at the end of the most recent quarter. 16.41% of the stock is currently owned by institutional investors.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com